MX357761B - Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. - Google Patents

Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.

Info

Publication number
MX357761B
MX357761B MX2013012526A MX2013012526A MX357761B MX 357761 B MX357761 B MX 357761B MX 2013012526 A MX2013012526 A MX 2013012526A MX 2013012526 A MX2013012526 A MX 2013012526A MX 357761 B MX357761 B MX 357761B
Authority
MX
Mexico
Prior art keywords
disease
methods
autism
huntington
disorders
Prior art date
Application number
MX2013012526A
Other languages
English (en)
Spanish (es)
Other versions
MX2013012526A (es
Inventor
Joseph Moskal
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2013012526A publication Critical patent/MX2013012526A/es
Publication of MX357761B publication Critical patent/MX357761B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2013012526A 2011-04-27 2012-04-27 Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. MX357761B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US201161527744P 2011-08-26 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Publications (2)

Publication Number Publication Date
MX2013012526A MX2013012526A (es) 2014-04-16
MX357761B true MX357761B (es) 2018-07-23

Family

ID=47073094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012526A MX357761B (es) 2011-04-27 2012-04-27 Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.

Country Status (13)

Country Link
US (4) US20140107037A1 (enExample)
EP (2) EP3679931A3 (enExample)
JP (1) JP6035326B2 (enExample)
KR (5) KR20210046843A (enExample)
CN (2) CN108283712A (enExample)
AU (1) AU2012249397B2 (enExample)
BR (1) BR112013027554A2 (enExample)
CA (1) CA2834286A1 (enExample)
EA (2) EA029999B1 (enExample)
HK (1) HK1258231A1 (enExample)
MX (1) MX357761B (enExample)
SG (2) SG194230A1 (enExample)
WO (1) WO2012149389A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20151436A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
EP3062810A4 (en) * 2013-10-28 2017-05-03 Naurex Inc. Nmda receptor modulators and prodrugs, salts, and uses thereof
EP3721799A1 (en) * 2013-12-13 2020-10-14 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
WO2015200322A1 (en) * 2014-06-23 2015-12-30 Northwestern University Methods of treating or ameliorating migraine
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
US20060167032A1 (en) * 2002-01-16 2006-07-27 Galer Bradley S Pharmaceutical composition and method for treating disorders of the central nervous system
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
PT2030622E (pt) * 2005-03-24 2011-06-02 Univ Emory Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico
CA2716375C (en) * 2008-02-20 2018-05-29 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
KR101769999B1 (ko) * 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie

Also Published As

Publication number Publication date
JP2014520072A (ja) 2014-08-21
CA2834286A1 (en) 2012-11-01
US20140107037A1 (en) 2014-04-17
US20190209642A1 (en) 2019-07-11
CN108283712A (zh) 2018-07-17
EA201391581A1 (ru) 2014-05-30
MX2013012526A (es) 2014-04-16
EP2701721A4 (en) 2015-12-16
KR20200043534A (ko) 2020-04-27
EA201790653A1 (ru) 2017-07-31
BR112013027554A2 (pt) 2016-09-06
KR20180095096A (ko) 2018-08-24
HK1258231A1 (zh) 2019-11-08
WO2012149389A2 (en) 2012-11-01
US20170049845A1 (en) 2017-02-23
SG194230A1 (en) 2013-12-30
KR20190037359A (ko) 2019-04-05
AU2012249397A1 (en) 2013-11-07
JP6035326B2 (ja) 2016-11-30
EP3679931A3 (en) 2020-10-14
SG10202010665YA (en) 2020-11-27
WO2012149389A3 (en) 2014-05-08
EP2701721A2 (en) 2014-03-05
US20210169964A1 (en) 2021-06-10
KR20140043078A (ko) 2014-04-08
CN103974712A (zh) 2014-08-06
EP3679931A2 (en) 2020-07-15
AU2012249397B2 (en) 2017-03-30
EA029999B1 (ru) 2018-06-29
KR20210046843A (ko) 2021-04-28

Similar Documents

Publication Publication Date Title
MX357761B (es) Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
MY195289A (en) Anti IL-36R Antibodies
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
MX349950B (es) Profarmacos de treprostinil enlazados a un portador.
IN2014CN02616A (enExample)
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
NZ716977A (en) Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
MY202135A (en) Uses of neuroactive compounds
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
MX2014004196A (es) Citramida de rasagilina.
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
MX2015006720A (es) D-metadona para el tratamiento de sintomas psiquiatricos.
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
EA201600088A1 (ru) Парентеральное введение тапентадола
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
PH12014500006A1 (en) Voltage-gated sodium channel blockers
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
WO2012151464A3 (en) Use of radiographic contrast agents for detecting dental caries

Legal Events

Date Code Title Description
FG Grant or registration